Get the Stockscreener App
1.21
5.47%
-0.07
Pre-market:
1.18
-0.03
-2.48%
Dermata Therapeutics Inc stock is traded at $1.21, with a volume of 225.15K.
It is down -5.47% in the last 24 hours and down -44.24% over the past month.
Dermata Therapeutics Inc develops and commercializes dermatology products for the treatment of common skin conditions. It focuses on leveraging prior clinical and technical expertise to develop OTC treatments for conditions such as acne, psoriasis, rosacea, and seborrheic dermatitis. The company is currently developing a once-weekly acne treatment system that utilizes an active ingredient from the OTC monograph in combination with the company's Spongilla technology for patients suffering with acne. It intends to apply its Spongilla technology platform across a range of dermatologic and aesthetic skin applications, including intradermal delivery of botulinum toxin.
See More
Previous Close:
$1.28
Open:
$1.22
24h Volume:
225.15K
Relative Volume:
0.12
Market Cap:
$3.43M
Revenue:
-
Net Income/Loss:
$-11.27M
P/E Ratio:
-0.0565
EPS:
-21.4132
Net Cash Flow:
$-9.40M
1W Performance:
-3.97%
1M Performance:
-44.24%
6M Performance:
-77.92%
1Y Performance:
-89.92%
1-Day Range:
$1.1554
$1.255
1-Week Range:
$1.1554
$2.29
52-Week Range:
$1.1554
$23.70
Dermata Therapeutics Inc Stock (DRMA) Company Profile
Name
Dermata Therapeutics Inc
Sector
Industry
Phone
(858)-223-0882
Address
3525 DEL MAR HEIGHTS RD., #322, SAN DIEGO
Compare DRMA vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DRMA
Dermata Therapeutics Inc
|
1.21 | 3.63M | 0 | -11.27M | -9.40M | -21.41 |
|
VRTX
Vertex Pharmaceuticals Inc
|
487.43 | 122.19B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
772.19 | 83.21B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
840.28 | 51.13B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
332.85 | 43.68B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
369.00 | 41.01B | 4.98B | 69.60M | 525.67M | 0.5198 |
Dermata Therapeutics Inc Stock (DRMA) Latest News
ARMISTICE CAPITAL, LLC Reduces Stake in Dermata Therapeutics Inc - GuruFocus
Update Report: Will Dermata Therapeutics Inc benefit from seasonalityPortfolio Performance Report & Weekly Return Optimization Alerts - baoquankhu1.vn
Growth Value: What is Dermata Therapeutics Incs valuation compared to sector2025 Winners & Losers & Technical Pattern Alert System - baoquankhu1.vn
Contrasting Qiagen (NYSE:QGEN) & Dermata Therapeutics (NASDAQ:DRMA) - Defense World
Chipmakers Recap: Can Dermata Therapeutics Inc Equity Warrant grow without external fundingJuly 2025 Rallies & Daily Risk Controlled Trade Plans - baoquankhu1.vn
12 Health Care Stocks Moving In Friday's Intraday Session - Benzinga
Growth Recap: Is Dermata Therapeutics Inc Equity Warrant benefiting from innovation trendsQuarterly Growth Report & Low Drawdown Trading Techniques - baoquankhu1.vn
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
Can Dermata Therapeutics Inc. expand into new markets2025 AllTime Highs & Verified Technical Trade Signals - mfd.ru
Can Dermata Therapeutics Inc. Equity Warrant stock double in the next yearWeekly Market Summary & AI Powered Market Trend Analysis - mfd.ru
How rising interest rates impact Dermata Therapeutics Inc. stockJuly 2025 Chart Watch & Verified Stock Trade Ideas - mfd.ru
Bristol Investment Fund Ltd. v. Dermata Therapeutics Inc.: Complaint (‘$160K Breach of Contract’) - OffshoreAlert
Bull Run: Can AVITA Medical Inc weather a recessionMarket Performance Summary & Precise Buy Zone Identification - baoquankhu1.vn
Will Dermata Therapeutics Inc. stock benefit from AI adoption2025 Momentum Check & AI Forecasted Entry/Exit Points - mfd.ru
Stock Report: Should I average down on Dermata Therapeutics Inc Equity Warrant stockJuly 2025 Short Interest & Real-Time Buy Signal Notifications - baoquankhu1.vn
Surprises Report: What are Twin Hospitality Group Incs technical support levels - baoquankhu1.vn
Is Dermata Therapeutics Inc a momentum stockTrade Volume Report & Long-Term Investment Growth Plans - baoquankhu1.vn
Aug Opening: What are the future prospects of iSpecimen Inc2025 Sector Review & Verified Momentum Stock Alerts - baoquankhu1.vn
Aug Weekly: Is Eureka Acquisition Corp Debt Equity Composite Units a cyclical or defensive stockGold Moves & Fast Moving Trade Plans - baoquankhu1.vn
Will Dermata Therapeutics Inc. Equity Warrant stock outperform Nasdaq indexJuly 2025 Update & Entry Point Confirmation Signals - mfd.ru
Loss Report: Is Dermata Therapeutics Inc Equity Warrant stock risky to hold nowWeekly Gains Summary & Verified Entry Point Detection - baoquankhu1.vn
History Review: Can ALUR disrupt its industryJuly 2025 Macro Moves & Growth Focused Stock Reports - baoquankhu1.vn
What is Dermata Therapeutics Inc.’s valuation compared to sectorJuly 2025 Spike Watch & Target Return Focused Picks - mfd.ru
Tuesday's after hours session: top gainers and losers - Chartmill
Meme Stocks: Is NRx Pharmaceuticals Inc Equity Warrant forming a breakout pattern2025 Market Overview & Expert Curated Trade Setups - baoquankhu1.vn
Dermata Therapeutics increases at-the-market offering by $705,000 - Investing.com Nigeria
Dermata Therapeutics increases at-the-market offering by $705,000 By Investing.com - Investing.com South Africa
Dermata Therapeutics Expands At-The-Market Equity Offering Capacity - TipRanks
Market Movers | Winners: GRI, XXII, LRHC | Losers: NBY, EMAT, APUS - Trefis
12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga
Gap Down: Why is AHLPRF stock going downMarket Activity Report & Accurate Intraday Trade Tips - baoquankhu1.vn
12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga
Whats next for M3 Brigade Acquisition V Corp stockJuly 2025 Spike Watch & Precise Buy Zone Identification - baoquankhu1.vn
12 Health Care Stocks Moving In Wednesday's After-Market Session - Benzinga
Aug Momentum: Does RRGB meet Warren Buffetts criteriaMarket Trend Summary & Precise Swing Trade Alerts - baoquankhu1.vn
Dermata receives Australian patent for Spongilla acne treatment By Investing.com - Investing.com Nigeria
Dermata receives Australian patent for Spongilla acne treatment - Investing.com
Dermata Receives Notice of Grant of Patent for Next-Generation Acne Treatment by Australian Patent Office - ACCESS Newswire
3.3M Australians with acne: Dermata's new treatment patent - Stock Titan
Will Dermata Therapeutics Inc. stock outperform growth indexesJuly 2025 Reactions & Stock Market Timing Techniques - bollywoodhelpline.com
Fundamentals Check: Will Dermata Therapeutics Inc benefit from seasonalityTrade Analysis Report & AI Driven Price Predictions - baoquankhu1.vn
Can Grace Therapeutics Inc. weather a recessionRate Cut & Safe Capital Growth Trade Ideas - bollywoodhelpline.com
How buybacks impact Dermata Therapeutics Inc. stock value2025 Trade Ideas & Verified Stock Trade Ideas - ulpravda.ru
Can Dermata Therapeutics Inc. Equity Warrant stock deliver consistent earnings growthQuarterly Profit Report & AI Based Trade Execution Alerts - ulpravda.ru
Axillary Hyperhidrosis Market to Evolve Rapidly Over the Next Decade by 2034, DelveInsight Observes | Botanix Pharma, Sound Surgical Tech, Dr. August Wolff GmbH, Medy-Tox, Journey Medical Corp. - Barchart.com
Will Dermata Therapeutics Inc. stock attract more institutional investorsFit and Size Notes & support options for steady strides - Улправда
Dermata Therapeutics Inc. (DRMA) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
What dividend safety score for Dermata Therapeutics Inc. Equity Warrant stockJuly 2025 Big Picture & Daily Profit Focused Screening - Улправда
Is Dermata Therapeutics Inc. stock a top pick in earnings seasonMarket Movers & Free Expert Verified Stock Movement Alerts - Улправда
Why Dermata Therapeutics Inc. Equity Warrant stock is popular among millennialsTrade Exit Summary & Smart Investment Allocation Insights - Улправда
Dermata Therapeutics Inc Stock (DRMA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.20%
0.26%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):